CPHI North America was successfully held at the Pennsylvania Convention Center in Philadelphia, USA, April 25-27, 2023. The exhibition brought together 356 exhibitors from all over the world and present 23 speeches delivered by authoritative guests on site. It attracted a large number of industry elites to join and share with each other and became an annual renowned event of the pharmaceutical industry. Laviana Pharma was invited to appear at the exhibition.

It is reported that CPhI North America is one of the pharmaceutical raw material and fine chemical exhibitions with most powerful influence in the United States. As a large-scale fine chemical exhibition in the United States, CPHI enjoys great popularity in the international chemical circle and covers the whole industry chain of pharmaceutical R&D, production and packaging. The exhibition is especially known for the Custom Chemical business.

During the exhibition, Laviana Pharma's booth draw attention from a large number of attendees, whom the company’s business team conducted in-depth communication and business negotiations with, demonstrating the advantages of the platform and one-stop solutions in the field of small molecule innovative drugs. In addition, Laviana Pharma also introduced its 66,000-square-meter GMP production base in Cangzhou and the upcoming New Drug & API Production and R&D Industrial Park. Attendees spoke highly of Laviana Pharma for its comprehensive strength and innovation capabilities.

This exhibition not only provides Laviana Pharma with an opportunity to showcase its strength, but also for the company to expand its global market. Laviana Pharma has a R&D team having professional knowledge and rich experience in the field of chemical R&D and manufacture, able to provide quality services in chemical R&D and manufacture. In the future, Laviana Pharma will actively participate in global pharmaceutical exhibitions and forums to facilitate global cooperation and exchange of pharmaceutical technology. It is dedicated to becoming a flagship CDMO enterprise to provide a full range of technical support for clients' new drug development, thus helping clients accelerate new drug development and launch to the market.